Continuous subcutaneous insulin infusion (CSII) is based on a continuous subcutaneous infusion of insulin delivered via an ex− ternal pump; therefore, basal insulin supply is better adapted to physiological needs with boli of insulin on demand for prandial coverage, which also provides more flexibility to insulin require− ment. Rapid−acting insulin analogues such as insulin lispro, insu− lin aspart and insulin glulisine begin to act more rapidly with the effect fading sooner than regular human insulin (RHI) after sub− cutaneous injection, and are therefore currently preferred in pa− tients with type 1 diabetes [1 ± 8]. The number of patients using pumps to deliver their daily insulin is increasing, and is estima− ted to be over 130 000 individuals worldwide (more than 80 000 of these are in the USA) [9] .
Abstract
This twelve−week, European, multicenter, controlled, open−label, randomized (1 : 1), parallel−group trial compared the safety of in− sulin glulisine with insulin aspart used in continuous subcuta− neous insulin infusion. Patients with type 1 diabetes (n = 59) and continuous subcutaneous insulin infusion experience (mean values: HbA 1c 6.9 % [insulin glulisine: 6.8 % vs. insulin as− part: 7.1 %]; age 45.8 years; body mass index 26.0 kg/m 2 ) were enrolled. HbA 1c levels at endpoint (insulin glulisine: 7.0 % vs. in− sulin aspart: 7.2 %), daily insulin doses, blood glucose profiles and adverse event rates were similar in both groups. The median (minimum±maximum) catheter occlusion rate was low for insu− lin glulisine and insulin aspart (0 [0 ± 0.7] vs. 0 [0 ± 1.1] occlu− sions/month. Unexplained hyperglycemia occurred in six insulin glulisine−treated patients and twelve insulin aspart−treated pa− tients. Patients were expected to change their catheters every 2 days (15 changes/month); the catheter change rate was similar for insulin glulisine and insulin aspart (14.1 vs. 14.8 changes/ month). The frequency of infusion site reactions and hypoglyce− mia, and the time between catheter changes were similar for both insulin forms. Diabetic ketoacidosis was not reported. This study supports the safety of insulin glulisine in continuous sub− cutaneous insulin infusion administered via an external pump in type 1 diabetes.
The faster onset and shorter duration of action compared with RHI [10, 11] suggest that rapid−acting insulin analogues would be highly suited in CSII. Indeed, previous studies have shown that the use of rapid−acting insulin analogues (insulin lispro) can improve glycemic control in CSII without an increased risk of hypoglycemia compared to RHI in patients with type 1 dia− betes [4, 12] .
This study was performed to demonstrate that insulin glulisine may be safely administered by CSII via an external pump to con− trol hyperglycemia in patients with type 1 diabetes. The study was designed to assess whether the physicochemical properties of insulin glulisine are compatible with pump use rather than testing for actual efficacy. The comparator used in the study was insulin aspart.
Materials and Methods

Patients
Patients eligible to participate in the study were male or female and aged >18 years, with type 1 diabetes and HbA 1c less than or equal to 8.5 %. All patients had been receiving insulin therapy for at least one year prior to study entry, with at least six months of CSII treatment immediately prior to the study. Patients had used the same type of external pump (MiniMed programmable pump, Disetronic H−Tron Plus V100, Disetronic D−Tron) for at least three months prior to study entry. Patients with a history of serious Ketosis episodes requiring hospitalization or abscess at the infu− sion site within the three months prior to study entry were ex− cluded from enrolment.
Study design
The study had an open−label, multicenter, randomized (1 : 1; centralized procedure), controlled, parallel−group design, and was conducted in accordance with Good Clinical Practice and the ethical principles of the Declaration of Helsinki. All study documentation was reviewed and approved by an independent Ethics Committee. Prior to screening and before admittance to the study, all patients gave their written informed consent.
Study protocol
The study consisted of a one−week screening phase, a four−week run−in phase in which all patients received insulin aspart, and a twelve−week treatment phase. During the treatment phase, pa− tients were administered a basal rate of insulin in addition to bo− lus doses of insulin glulisine or insulin aspart immediately be− fore meals using CSII. Bolus doses and the basal infusion rate were adjusted according to the opinion of the investigator and the needs of the individual in order to achieve treatment goals of fasting and pre−prandial blood glucose concentrations of 5.0 ± 6.7 mmol/l (90 ± 120 mg/dl), and two−hour postprandial (two hours after the start of a meal) blood glucose concentra− tions of 6.7 ± 8.9 mmol/l (120 ± 160 mg/dl), all without encoun− tering hypoglycemia.
Full instructions on use of the study equipment were given. Pa− tients were trained to fill the pump reservoir, to use the infusion set and to insert the catheter. Patients were then instructed to change the infusion set and reservoir every 2 days (15 changes per month).
Objectives
The primary objective of the study was to evaluate the compat− ibility of insulin glulisine with pump use by specifically compar− ing the safety of insulin glulisine and insulin aspart when used in external pumps in terms of specific external pump parameters: catheter occlusions, rate of catheter changes, time interval be− tween catheter changes, infusion site reactions and unexplained hyperglycemia. Secondary objectives were to compare the ef− fects of insulin glulisine and insulin aspart treatments on blood glucose parameters: glycated hemoglobin (GHb; measured as HbA 1c equivalents), hypoglycemia, insulin doses, adverse events, laboratory data and vital signs.
Measurement of glycated hemoglobin
Glycated hemoglobin (GHb) was measured at the Diabetes Diag− nostic Laboratory (certified by the National Glycohemoglobin Standardization Program) using affinity chromatography. Results are reported as 'HbA 1c equivalents' as used in the Diabetes Con− trol and Complications Trial (DCCT) [13] .
Study assessments
Any catheter occlusions or leakage of the infusion set were re− corded in each patient's diary, together with the date and time of change of the infusion set (both planned and forced). Episodes of unexplained hyperglycemia, defined as blood glucose concen− trations above 19.4 mmol/l (> 350 mg/dl) not due to any apparent medical, dietary, insulin dosing or pump failure were also noted. Symptomatic, nocturnal and severe symptomatic hypoglycemic episodes were all monitored in this study. Severe hypoglycemia was defined as an event with clinical symptoms resulting from hypoglycemia that required assistance from another person, confirmed by blood glucose less than 2.0 mmol/l (< 36 mg/dl), or with prompt recovery following oral carbohydrate, intravenous glucose or glucagon administration.
The study investigator observed patients for local or systemic treatment−emergent adverse events (TEAEs), and patients re− ported any such events that occurred during the study. Severe symptomatic hypoglycemia was systematically reported as a possibly related serious TEAE. Lipid levels, hematological param− eters and clinical chemistry were also analyzed.
Statistics
No formal sample−size calculation was performed for this study. The intention−to−treat (ITT) population was defined as all ran− domized patients receiving study medication. Patients with missing baseline data or no value for a specific variable collected during the treatment phase were not included in statistical anal− ysis for that variable. Mean differences between the two treat− ment groups were calculated and their corresponding 95 % confi− dence intervals (CI) provided for monthly rate of catheter occlu− sions, monthly rate of catheter changes, HbA 1c and blood glucose. A frequency distribution with the percentage difference between treatment groups and their 95 % CI was calculated for catheter occlusions; unexplained hyperglycemia; the proportions of pa− tients with a decrease in HbA 1c from baseline values of at least 0.7 % at week 12 and endpoint; fasting blood glucose and symp− tomatic hypoglycemia.
Laboratory values and vital signs were analyzed at baseline using analysis of variance (ANOVA) with treatment and center (pooled) as fixed effects. Changes from baseline to week 12 and to endpoint were evaluated using analysis of covariance (ANCO− VA) with treatment and center (pooled) as fixed effects and the corresponding baseline value as covariate.
Results
Patients
This multicenter study was performed at eight centers in three European countries: France (3 centers; 17 patients), Germany (3 centers; 31 patients) and The Netherlands (2 centers; 24 pa− tients). A total of 72 patients entered the screening phase, during which thirteen patients were withdrawn. The reasons for these withdrawals were: the patient no longer met the study criteria (n = 7), the patient did not wish to continue (n = 4), lack of effica− cy with insulin aspart (n = 1), and hypoglycemia (n = 1). A total of 59 patients were randomized to insulin glulisine (n = 29) or insu− lin aspart (n = 30). All of these patients received study medica− tion and comprised the ITT population.
During the treatment phase, two patients withdrew (one patient in the insulin glulisine group following a suicide attempt, and one patient in the insulin aspart group that did not wish to con− tinue). The median duration of treatment during the treatment phase was 85 days in both treatment groups.
Baseline characteristics
Baseline characteristics for all patients are presented in Table 1 . No notable between−treatment differences were observed.
Catheter occlusions or changes
All 59 patients were included in the analysis of catheter occlu− sions. The rates and numbers of catheter occlusions reported during the treatment phase are presented in Table 2 .
During the treatment phase, four patients (13.8 %) in the insulin glulisine group reported at least one catheter occlusion compar− ed with eight patients (26.7 %) in the insulin aspart group. Al− though not statistically significant, this was associated with a treatment difference of ± 12.9 % in favor of insulin glulisine (95 % CI: ± 33.1, 7.3). The median (minimum−maximum [mean]) rate of catheter occlusions per month was 0 (0 ± 0.7 [0.1 0.2]) for insulin glulisine and 0 (0 ± 1.1 [0.2 0.3]) for insulin aspart, and, although not statistically significant, was associated with a treat− ment difference of ± 0.1 in favor of insulin glulisine (95 % CI: ± 0.2, 0.1). The time between catheter changes was similar for patients with catheter occlusions and those without. The mean rate of catheter changes was also similar for the two treatment groups (14.1 vs. 14.8 changes/month for insulin glulisine and insulin as− part, respectively). The mean time between catheter changes was 2.1 0.3 days (range 1.6 ± 3.4 days) for insulin glulisine and 2.0 0.2 days (range 1.4 ± 2.7 days) for insulin aspart.
Unexplained hyperglycemia
At least one instance of unexplained hyperglycemia was reported for six patients (20.7 %) receiving insulin glulisine and twelve pa− tients (40.0 %) receiving insulin aspart. None of these cases were 
Glycemic control
Both treatment groups showed a slight increase in mean HbA 1c over the study period, with a mean change from baseline to end− point of 0.2 % (from 6.8 % to 7.0 %) in the insulin glulisine group and 0.1 % (from 7.1 % to 7.2 %) in the insulin aspart group with a between−treatment difference of 0.11 (95 % CI: ± 0.09, 0.31). Self− monitored seven−point blood glucose variables showed no nota− ble differences between treatment groups for any measurements throughout the study (data not shown).
Hypoglycemia
The number of hypoglycemic episodes and the proportion of pa− tients experiencing hypoglycemic episodes are presented in Ta− ble 3. Few patients reported severe symptomatic hypoglycemia in either group, and numbers were similar.
Insulin dose and regimen
The mean total daily insulin dose was similar for both insulin glulisine and insulin aspart at baseline (42.8 vs. 42.9 IU) and at endpoint (43.3 vs. 44.4 IU) with a treatment difference of ± 1.1 (95 % CI: ± 4.8, 2.7). Mean daily bolus insulin dose increased slightly in both groups (+ 1.0 IU for insulin glulisine and + 1.5 IU for insulin aspart). Mean daily basal insulin dose decreased by 0.48 IU in the insulin glulisine group, but was relatively un− changed in the insulin aspart group (+ 0.09 IU).
Treatment emergent adverse events
Treatment emergent adverse events occurred in 14 (48.3 %) and 20 (66.7 %) patients receiving insulin glulisine and insulin aspart, respectively. Five patients (17.2 %) experienced serious adverse events in the insulin glulisine group, compared with four (13.3 %) patients in the insulin aspart group; none of the serious nonhypoglycemia adverse events were deemed to be possibly related to study medication.
One case of injection site inflammation and injection site pain was reported in each treatment group. In the insulin glulisine group, there was one case of injection site pruritus, which was possibly treatment−related. There were no significant differences in hematology, clinical chemistry, body weight or vital signs be− tween the treatment groups at baseline or at endpoint.
Discussion and Conclusions
The main purpose of this study was to compare the safety of in− sulin glulisine (a new rapid−acting insulin analogue) with insulin aspart (approved for use in pump therapy) when used in CSII. Ra− pid−acting insulin analogues have been developed for use in multiple daily injection regimens and regimens that include sub− cutaneous injection in combination with CSII, and therefore re− quire careful evaluation to ensure their compatibility with CSII. In particular, catheter occlusions could cause rapid increases in glycemia with the use of rapid−acting insulin analogues in CSII compared with regular insulin [14] .
In this study, there was a low and similar rate of catheter occlu− sions in both the insulin glulisine and insulin aspart treatment groups, and the overall rate of catheter changes (both planned and forced) was also similar in both groups. Insulin glulisine− treated patients did show a trend towards fewer catheter occlu− sions compared with insulin aspart−treated patients (which may be explained by zinc−free formulation with polysorbate 20 as a detergent, which reduces the likelihood of surface−to−insulin in− teraction and thus contributes to reducing fibrillation and clot− ting); however, the limited sample size of the study prevents de− finitive conclusions regarding superiority to be drawn. Although this was a relatively short study, it was of similar or longer dura− tion than comparable studies conducted with other rapid−acting insulin analogues [1 ± 5, 8,15] . However, the study was designed under the common assumption that the majority of catheter oc− clusions and adverse events will be observed within the first month of treatment.
There were fewer TEAEs in the insulin glulisine group compared with the insulin aspart group. Although serious adverse events were more frequent in the insulin glulisine group compared to insulin aspart, none of these were deemed to be possibly related to the study medication. In addition, there were no notable be− tween−treatment differences in terms of injection site reactions or in the frequency of serious non−hypoglycemic TEAEs. Further− more, there were no concerns about hypoglycemia reported as a serious TEAE, which occurred in a similar proportion of patients in both groups.
In conclusion, these data demonstrate that insulin glulisine can be safely used in CSII and does not have any adverse clinical im− plications for patients compared with another insulin analogue that has been approved for pump use in the USA and Europe. The results of this study, therefore, support the use of insulin glu− lisine in CSII therapy administered via an external pump. Original Clinical
